IRIS
PICHINI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.318
AS - Asia 2.256
EU - Europa 2.041
SA - Sud America 373
Continente sconosciuto - Info sul continente non disponibili 176
AF - Africa 155
OC - Oceania 12
Totale 11.331
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.188
SG - Singapore 865
IT - Italia 527
RU - Federazione Russa 380
CN - Cina 375
VN - Vietnam 375
BR - Brasile 288
HK - Hong Kong 268
FR - Francia 197
DE - Germania 157
IE - Irlanda 154
SE - Svezia 132
GB - Regno Unito 130
UA - Ucraina 110
IN - India 92
BD - Bangladesh 73
CI - Costa d'Avorio 69
CA - Canada 56
NL - Olanda 52
MX - Messico 50
FI - Finlandia 48
JP - Giappone 35
PL - Polonia 33
ZA - Sudafrica 30
BE - Belgio 28
IQ - Iraq 27
TR - Turchia 27
AR - Argentina 23
AT - Austria 20
ES - Italia 19
EC - Ecuador 17
MA - Marocco 15
PK - Pakistan 15
CO - Colombia 13
ID - Indonesia 13
PH - Filippine 12
VE - Venezuela 11
TH - Thailandia 10
CL - Cile 9
AE - Emirati Arabi Uniti 8
AU - Australia 8
EG - Egitto 8
KR - Corea 8
TN - Tunisia 7
DK - Danimarca 6
DZ - Algeria 6
IL - Israele 6
IR - Iran 6
SA - Arabia Saudita 6
UZ - Uzbekistan 6
BG - Bulgaria 5
JM - Giamaica 5
KE - Kenya 5
LT - Lituania 5
MY - Malesia 5
NP - Nepal 5
ET - Etiopia 4
MD - Moldavia 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
RO - Romania 4
RS - Serbia 4
UY - Uruguay 4
AZ - Azerbaigian 3
BY - Bielorussia 3
CH - Svizzera 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
HN - Honduras 3
MT - Malta 3
OM - Oman 3
PA - Panama 3
PE - Perù 3
TW - Taiwan 3
BO - Bolivia 2
HU - Ungheria 2
JO - Giordania 2
MO - Macao, regione amministrativa speciale della Cina 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AL - Albania 1
BB - Barbados 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CD - Congo 1
CM - Camerun 1
DM - Dominica 1
EE - Estonia 1
EU - Europa 1
GA - Gabon 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
Totale 11.144
Salva come PNG Salva come JPEG
Città #
Ashburn 990
Singapore 568
Dallas 532
Chandler 328
San Jose 309
Hong Kong 263
Des Moines 240
Fairfield 226
Council Bluffs 202
Jacksonville 176
Dublin 155
New York 152
Los Angeles 134
Beijing 133
Seattle 122
Houston 113
Boardman 110
Ho Chi Minh City 109
Wilmington 106
Hanoi 99
Woodbridge 96
Cambridge 82
Lauterbourg 78
The Dalles 76
Moscow 70
Abidjan 69
Rome 65
Lawrence 58
Princeton 58
Munich 54
Milan 52
San Mateo 48
Ann Arbor 43
Denver 43
San Francisco 42
São Paulo 42
Orem 41
Santa Clara 41
Atlanta 38
Chicago 38
London 38
Phoenix 38
Buffalo 37
Turin 36
Ancona 32
Helsinki 32
Mexico City 29
Warsaw 29
Brooklyn 26
Tokyo 26
Montreal 25
Hefei 24
San Diego 23
Da Nang 21
Pune 21
Boston 20
Frankfurt am Main 20
Haiphong 20
Brussels 18
Toronto 18
Chennai 17
Baghdad 16
Memphis 16
Turku 15
Washington 15
Johannesburg 14
Shanghai 14
Amsterdam 13
Manchester 13
Miano 13
Centro 11
Stockholm 11
Vienna 11
Boydton 10
Columbus 10
Falls Church 10
Poplar 10
Honolulu 9
Kilburn 9
Mohali 9
Cape Town 8
Guarulhos 8
Pittsburgh 8
Querétaro 8
Quito 8
Rio de Janeiro 8
Canary Wharf 7
Florence 7
Guangzhou 7
Izmir 7
Jinan 7
Messina 7
Norwalk 7
Salt Lake City 7
San Antonio 7
Tukwila 7
Verona 7
Wuhan 7
Ahmedabad 6
Ankara 6
Totale 7.124
Salva come PNG Salva come JPEG
Nome #
UHPLC-MS-MS Determination of THC, CBD and Their Metabolites in Whole Blood of Light Cannabis Smokers 570
Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use 390
THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis" 300
A comprehensive HPLC–MS-MS screening method for 77 new psychoactive substances, 24 classic drugs and 18 related metabolites in blood, urine and oral fluid 289
Maternal hair testing to disclose self-misreporting in drinking and smoking behavior during pregnancy 247
Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis 240
Human diagnostic markers for intake of semi-synthetic cannabinoids (9R)- and (9S)-hexahydrocannabinol 238
Human metabolism and pharmacological profiling of protonitazepyne and metonitazepyne, two highly potent nitazenes: prediction of main metabolite activity based on µ-opioid receptor docking simulations 225
Disposition of phytocannabinoids, their acidic precursors and their metabolites in biological matrices of healthy individuals treated with vaporized medical cannabis 220
Acute Pharmacological Effects and Oral Fluid Concentrations of the Synthetic Cannabinoids JWH-122 and JWH-210 in Humans After Self-Administration: An Observational Study 207
New challenges in clinical and forensic toxicology 180
Analysis of perfluoroalkyl substances (PFAS) in conventional and unconventional matrices: Clinical outcomes 166
Disposition of Hexahydrocannabinol Epimers and Their Metabolites in Biological Matrices following a Single Administration of Smoked Hexahydrocannabinol: A Preliminary Study 165
Acute Intoxications and Fatalities Associated with Benzimidazole Opioid (Nitazene Analog) Use: A Systematic Review 165
“Tranq-dope”: The first fatal intoxication due to xylazine-adulterated heroin in Italy 159
Disposition of cannabidiol metabolites in serum and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis 158
Stability and Degradation Pathways of Different Psychoactive Drugs in Neat and in Buffered Oral Fluid 156
Monitoring Prenatal Exposure to Buprenorphine and Methadone 152
Toxicology and analysis of psychoactive tryptamines 148
Dipyanone, a new methadone-like synthetic opioid: In vitro and in vivo human metabolism and pharmacological profiling 141
Herbal preparations of medical cannabis: A vademecum for prescribing doctors 138
Usefulness of Oral Fluid for Measurement of Methylone and Its Metabolites: Correlation with Plasma Drug Concentrations and the Effect of Oral Fluid pH 137
Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids 137
Analytical procedures and blood threshold values to ascertain driving in a stae of psycho-physical impairment from drugs abuse|Procedure analitiche e valori decisionali ematici per accertare la guida in stato di alterazione psicofisica da sostanze d'abuso 134
Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans 133
Acute Intoxications and Fatalities From Illicit Fentanyl and Analogues: An Update 133
Analytical Strategies to Disclose Repeated Consumption of New Psychoactive Substances by Hair Analysis 133
QuEChERS Extraction and Simultaneous Quantification in GC-MS/MS of Hexahydrocannabinol Epimers and Their Metabolites in Whole Blood, Urine, and Oral Fluid 130
UHPLC-MS/MS analysis of cannabidiol metabolites in serum and urine samples. Application to an individual treated with medical cannabis 130
Determination of the synthetic cannabinoids JWH-122, JWH-210, UR-144 in oral fluid of consumers by GC-MS and quantification of parent compounds and metabolites by UHPLC-MS/MS 130
Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry 130
Commentary - Heroin purity and adulteration: An updated snapshot from the Italian Early Warning System 128
UHPLC-MS/MS analysis of cannabidiol and its metabolites in serum of patients with resistant epilepsy treated with CBD formulations 124
Ultra-high-performance liquid chromatography-tandem mass spectrometry assay for quantifying fentanyl and 22 analogs and metabolites in whole blood, urine, and hair 122
European drug users at risk from illicit fentanyls mix 122
Pharmacological effects of methylone and MDMA in humans 122
A fatal chemsex case involving γ-butyrolactone and 4-methylethcathinone 121
Cannabinoids determination in bronchoalveolar lavages of cannabis smokers with lung disease 119
Pharmacology and legal status of cannabidiol 118
Correspondence 118
Monitoring Perinatal Exposure to Cannabis and Synthetic Cannabinoids 117
Cannabidiol adverse effects and toxicity 116
Analytical advances in clinical and forensic toxicology. Second part 114
The National Early Warning System, a web-based platform to prevent the spread of New Psychoactive Substances 114
Liquid Chromatography High-Resolution Mass Spectrometry in Forensic Toxicology: What are the Specifics of Method Development, Validation and Quality Assurance for Comprehensive Screening Approaches? 113
Dilute and shoot ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC–MS/MS) analysis of psychoactive drugs in oral fluid 113
Evaluation of Short-Term Stability of Different Nitazenes Psychoactive Opioids in Dried Blood Spots by Liquid Chromatography-High-Resolution Mass Spectrometry 112
Sweat Testing for the Detection of Methylone after Controlled Administrations in Humans 111
Measurement uncertainty in forensic toxicology 111
Recent challenges and trends in forensic analysis: Δ9-THC isomers pharmacology, toxicology and analysis 108
Comment on "direct Monitoring of Exogenous γ-Hydroxybutyric Acid in Body Fluids by NMR Spectroscopy": Several Issues to Consider When Quantifying γ-Hydroxybutyric Acid in Biological Matrixes 108
Ultra-high-performance liquid chromatography tandem mass spectrometry assay for determination of endogenous ghb and ghb-glucuronide in nails 104
Advances and future developments in forensic toxicology: From standard practices to new psychoactive substances 103
Determination of cannabinoids in oral fluid and urine of "light cannabis" consumers: A pilot study 102
Effects of subtoxic 3-methylmethcathinone concentrations on neuronal cell electrical properties 101
Herbal highs: Review on Psychoactive Effects and Neuropharmacology 101
Synthetic cathinones related fatalities: an update 101
A “special dose” of ethics in forensic toxicology 99
Clarifying methodological issues in cannabinoids determination in bronchoalveolar lavages 99
Development of enantioselective high-performance liquid chromatography-tandem mass spectrometry method for quantitative determination of methylone and some of its metabolites in oral fluid 99
Pharmacotoxicology of non-fentanyl derived new synthetic opioids 98
Medicinal cannabis and synthetic cannabinoid use 97
Screening methods for rapid determination of new psychoactive substances (NPS) in conventional and non-conventional biological matrices 96
Correlation between Blood and Oral Fluid Psychoactive Drug Concentrations and Cognitive Impairment in Driving under the Influence of Drugs 94
Cannabis: Neurological correlates in abuse and medical use 94
The complex and constantly evolving public health threat of new psychoactive substances in Italy: Addressing the main functions of a national observatory of drugs 92
Segmental hair testing of triazolam to unmask a suspected case of idiopathic recurrent Stupor 90
Comprehensive Monitoring of Psychoactive Substances in Psychiatric Patients Using Liquid Chromatography-High-Resolution Mass Spectrometry: A Key Tool for Treatment Planning and Understanding Consumption Patterns in Rome, Italy 89
Metabolic pathways and potencies of new fentanyl analogs 87
Erratum to Reduced prevalence of fetal exposure to alcohol in Italy: a nationwide survey American Journal of Obstetrics & Gynecology MFM. Volume 5, Issue 6, June 2023, 100944 84
The issue of psychotropic drug monitoring in sexual assault victims 83
Global prevalence of fetal alcohol spectrum disorder in Italy 82
Stability of cannabinoids in cannabis FM1 flowering tops and oil preparation evaluated by ultra-high performance liquid chromatography tandem mass spectrometry 79
GHB concentration in breast milk of narcoleptic women treated with sodium oxybate. How important it is to be careful when interpreting values 76
The importance of biomarkers of fetal exposure to alcohol and psychotropic drugs in early diagnosis: A case report 76
Molecular Insights of New Psychoactive Substances (NPS) 2.0 76
Molecular Insights on New Psychoactive Substances (NPSs) 73
Editorial: Drug-drug interactions in pharmacology 72
GHB side effects: The need to clearly document drug dose and administration history 71
Target Analysis of NPS in Oral Fluid 69
New psychoactive substances: A matter of time 66
Editorial: Analytical Advances in Clinical and Forensic Toxicology 65
Editorial: The challenge posed by new synthetic opioids: Pharmacology and toxicology 65
Nails in Forensic Toxicology: an Update 63
The new synthetic benzimidazole opioid etonitazepipne: an emerging fatal harm and a challenge for laboratory medicine 62
The value of toxicological and forensic analyses in the global challenge to health risks caused by new psychoactive substances 58
GHB-facilitated sexual assaults: How to proper assess a single GHB exposure in hair 53
Totale 11.331
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.196
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.196
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022397 0 58 18 7 3 41 4 29 46 34 55 102
2022/20231.093 88 124 79 75 45 308 8 59 211 3 75 18
2023/2024590 79 12 80 53 83 115 26 20 8 17 14 83
2024/20251.693 117 118 88 71 86 124 141 92 347 115 154 240
2025/20264.878 351 480 336 343 537 256 820 394 361 417 182 401
2026/20271.551 1.004 547 0 0 0 0 0 0 0 0 0 0
Totale 11.331